Please assess the completion status of the following clinical trial:

Trial Title: Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Patient and family must agree to return to the clinic up to 8 times within 2 months~* Children ≥ 8 and \<18 years of age at the time of study entry who were previously treated for:~* a hypothalamic tumor~* mid-line brain tumor~* a tumor involving one or both thalami~* craniopharyngioma~* diagnosis of hydrocephalus secondary to a brain tumor or treatment of a brain tumor that required placement of a permanent shunt.~* Off cancer treatment for at least six months~* Proficient in English~* Able to swallow capsules~* Experiencing symptoms of excessive daytime sleepiness (EDS) for at least three months prior to study entry that is not a result of inadequate sleep hygiene or other known medical disorder.~* Negative pregnancy test~EXCLUSION CRITERIA:~* Patients treated with doxorubicin or high dose cyclophosphamide~* History of a clinically significant drug sensitivity to methylphenidate, modafinil, armodafinil or any of their components~* Known cardiac disorders including arrhythmias, hypertension requiring treatment or structural heart disease~* Have taken methylphenidate or modafinil within the last 14 days~* Current/concurrent use of antihistamines, benzodiazepine, anticonvulsants or alcohol~* Clinical diagnosis of major depression, subclinical depression, or anxiety disorder~* History of psychosis or mania~* Patients with suicidal ideation~* Diagnosis with anemia, untreated hypothyroidism, mononucleosis or narcolepsy~* History of substance abuse~* Pregnant or breast feeding~* A total dietary intake of more than 500 mg of caffeine per day (e.g., approximately ten 330 mL cans of soft drinks, five cups of coffee or tea, or 750 g chocolate per day).

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Arm I - methylphenidate hydrochloride (Type: EXPERIMENTAL): Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.
- Arm II -modafinil (Type: EXPERIMENTAL): Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.
- Arm III placebo (Type: PLACEBO_COMPARATOR): Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).